- Home
- LXEH vs BDRX Comparison
LXEH vs BDRX Comparison
Compare LXEH & BDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LXEH | BDRX |
|---|---|---|
| Founded | 2001 | 2000 |
| Country | China | United Kingdom |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4M | 2.0M |
| IPO Year | 2020 | 2015 |
Fundamental Metrics
Financial Performance| Metric | LXEH | BDRX |
|---|---|---|
| Price | $0.97 | $3.08 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 357.4K | 84.2K |
| Earning Date | 05-01-2026 | 09-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.16 | $0.60 |
| 52 Week High | $3.67 | $11.88 |
Technical Indicators
Market Signals| Indicator | LXEH | BDRX |
|---|---|---|
| Relative Strength Index (RSI) | 58.10 | 55.41 |
| Support Level | $0.21 | $2.86 |
| Resistance Level | $1.70 | $4.39 |
| Average True Range (ATR) | 0.12 | 0.27 |
| MACD | -0.02 | -0.14 |
| Stochastic Oscillator | 52.56 | 8.45 |
Price Performance
Historical ComparisonAbout LXEH Lixiang Education Holding Co. Ltd.
Lixiang Education Holding Co Ltd is a private primary and secondary education service provider in Lishui City, Zhejiang Province. Its private education services primarily include primary and middle school education from grade 1 to grade 9. The company also offers high school education services at its High School Divisions.
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.